Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Statin wars: the heavyweight match--atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease.

DiNicolantonio JJ, Lavie CJ, Serebruany VL, O'Keefe JH.

Postgrad Med. 2013 Jan;125(1):7-16. doi: 10.3810/pgm.2013.01.2620. Review.

PMID:
23391667
3.

Managing dyslipidemia in the high-risk patient.

Stein EA.

Am J Cardiol. 2002 Mar 7;89(5A):50C-57C. Review.

PMID:
11900720
6.

Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?

Fabbri G, Maggioni AP.

Adv Ther. 2009 May;26(5):469-87. doi: 10.1007/s12325-009-0025-6. Epub 2009 May 14. Review.

PMID:
19444394
7.

A meta-analysis of randomized head-to-head trials for effects of rosuvastatin versus atorvastatin on apolipoprotein profiles.

Takagi H, Umemoto T; ALICE (All-Literature Investigation of Cardiovascular Evidence) Group.

Am J Cardiol. 2014 Jan 15;113(2):292-301. doi: 10.1016/j.amjcard.2013.08.043. Epub 2013 Oct 3. Review.

PMID:
24230979
8.

Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.

Kostapanos MS, Milionis HJ, Elisaf MS.

Am J Cardiovasc Drugs. 2010;10(1):11-28. doi: 10.2165/13168600-000000000-00000. Review.

PMID:
20104931
9.

Rosuvastatin: a review of its use in the management of dyslipidemia.

Scott LJ, Curran MP, Figgitt DP.

Am J Cardiovasc Drugs. 2004;4(2):117-38. Review. Erratum in: Am J Cardiovasc Drugs. 2005;5(2):130.

PMID:
15049723
10.
11.

Rosuvastatin: a risk-benefit assessment for intensive lipid lowering.

Ferdinand KC.

Expert Opin Pharmacother. 2005 Sep;6(11):1897-910. Review.

PMID:
16144509
12.

Rosuvastatin in the management of hyperlipidemia.

Cheng JW.

Clin Ther. 2004 Sep;26(9):1368-87. Review.

PMID:
15531000
13.

Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs.

Campese VM.

Clin Exp Nephrol. 2014 Apr;18(2):291-5. doi: 10.1007/s10157-014-0934-9. Epub 2014 Feb 18. Review.

PMID:
24535025
14.

Rosuvastatin and cardiovascular disease: did the strongest statin hold the initial promises?

Efthimiadis A.

Angiology. 2008 Apr-May;59(2 Suppl):62S-4S. doi: 10.1177/0003319708321668. Epub 2008 Jul 15. Review.

PMID:
18628276
15.

Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA.

Barrios V, Escobar C.

Expert Rev Cardiovasc Ther. 2009 Nov;7(11):1317-27. doi: 10.1586/erc.09.119. Review.

PMID:
19900015
16.

A review of the efficacy of rosuvastatin in patients with type 2 diabetes.

Tuomilehto J, Leiter LA, Kallend D.

Int J Clin Pract Suppl. 2004 Oct;(143):30-40. Review.

PMID:
16035394
17.

Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).

Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ.

Am J Cardiol. 2010 Jan 1;105(1):69-76. doi: 10.1016/j.amjcard.2009.08.651. Review.

PMID:
20102893
18.

Efficacy and safety of rosuvastatin in treatment of dyslipidemia.

McKenney JM.

Am J Health Syst Pharm. 2005 May 15;62(10):1033-47. Review.

PMID:
15901588
19.

[Choosing wisely when prescribing statins].

Willemsen AE, Bredie SJ, Lobo CM, van der Vlugt MJ, Kramers C.

Ned Tijdschr Geneeskd. 2015;159:A8695. Review. Dutch.

PMID:
25990330
20.

Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.

Olsson AG, McTaggart F, Raza A.

Cardiovasc Drug Rev. 2002 Winter;20(4):303-28. Review.

PMID:
12481202

Supplemental Content

Support Center